COPD Pharmacotherapy

COPD pharmacotherapy is centered on bronchodilation, reduction of symptoms and exacerbations, preservation of function, and treatment of modifiable risk factors. Unlike asthma, COPD generally begins with bronchodilator therapy, while inhaled corticosteroids (ICSs) are added selectively according to exacerbation history, blood eosinophil count, coexisting asthma, and adverse-effect risk (GOLD, 2026; Wietholter & Whetsel, 2026).

COPD inflammation is commonly dominated by neutrophils, macrophages, and lymphocytes rather than the eosinophil- and mast-cell-predominant pattern typical of asthma. A subset of patients with COPD has increased eosinophils and is more likely to respond to corticosteroid-containing therapy (Wietholter & Whetsel, 2026).

Treatment Goals

COPD treatment seeks to reduce dyspnea, exercise limitation, and disease impact while preventing exacerbations, hospitalization, progression, and premature mortality. Treatment is individualized according to symptom burden, exacerbation history, adverse effects, comorbidities, medication availability and cost, patient preference, and ability to use the prescribed delivery device (GOLD, 2026).

GOLD ABE Initial Treatment Framework

GOLD 2026 uses the ABE framework to guide initial pharmacologic treatment. Group A includes patients with no moderate or severe exacerbations in the previous year and lower symptom burden (mMRC 0–1 or CAAT <10); a bronchodilator is used. Group B includes patients with no moderate or severe exacerbations in the previous year and greater symptom burden (mMRC ≥2 or CAAT ≥10); LABA/LAMA combination therapy is preferred. Group E includes patients with one or more moderate or severe exacerbations in the previous year regardless of symptom burden; LABA/LAMA is preferred, with consideration of triple LABA/LAMA/ICS therapy when blood eosinophils are ≥300 cells/µL (GOLD, 2026).

The 2026 framework is important because the Group E threshold is now one or more moderate or severe exacerbations in the previous year. This places greater emphasis on exacerbation prevention earlier in treatment.

Long-Acting Bronchodilators

LABA

LABAs used in COPD include formoterol, arformoterol, olodaterol, salmeterol, and vilanterol. They relax airway smooth muscle and improve symptoms and airflow. Adverse effects can include tremor, palpitations, tachycardia, cough, and hypokalemia.

LAMA

LAMAs include tiotropium, umeclidinium, glycopyrrolate, aclidinium, and revefenacin. By blocking muscarinic M3-mediated bronchoconstriction, they provide sustained bronchodilation. Dry mouth is common, while urinary retention and narrow-angle glaucoma are important precautions in susceptible patients.

LABA and LAMA mechanisms are complementary. Fixed-dose LABA/LAMA products can improve treatment simplicity and adherence while providing more bronchodilation than either class alone (GOLD, 2026; Wietholter & Whetsel, 2026).

Rescue Bronchodilation

A SABA is commonly used for acute breakthrough symptoms. Ipratropium, a SAMA, can also contribute to bronchodilation during exacerbations. When a patient already receives a LAMA for maintenance, a SABA is generally preferred for routine rescue to avoid unnecessary anticholinergic exposure (Wietholter & Whetsel, 2026).

Inhaled Corticosteroids

ICS therapy is not COPD monotherapy. LABA/ICS dual therapy is no longer the preferred COPD combination for new treatment decisions; when ICS is indicated, triple LABA/LAMA/ICS therapy is generally preferred (GOLD, 2026). Patients already stable on LABA/ICS may sometimes continue it depending on symptoms, exacerbation history, eosinophils, and prior response.

Factors that strongly favor ICS use include hospitalization for COPD exacerbation, at least two moderate exacerbations per year, blood eosinophils of 300 cells/µL or higher, and a history of or concomitant asthma. One moderate exacerbation per year or blood eosinophils between 100 and 299 cells/µL can favor ICS use. Repeated pneumonia, blood eosinophils below 100 cells/µL, and a history of mycobacterial infection argue against routine ICS use (GOLD, 2026).

Triple therapy can improve lung function, health status, and exacerbation outcomes and can reduce mortality in selected symptomatic patients with frequent or severe exacerbations, but it also increases pneumonia risk compared with LABA/LAMA therapy (GOLD, 2026; Wietholter & Whetsel, 2026).

Persistent Symptoms and Follow-Up Escalation

GOLD separates follow-up treatment according to the problem that persists. A patient with ongoing dyspnea on a single long-acting bronchodilator should generally escalate to LABA/LAMA. Persistent dyspnea despite dual bronchodilation should prompt reassessment of inhaler technique and adherence, consideration of another device or molecule, optimization of nonpharmacologic therapy, and investigation of other causes of breathlessness.

Continued moderate or severe exacerbations require a different pathway. Escalation is guided by current therapy and blood eosinophil count, with triple therapy increasingly favored as eosinophil count and exacerbation risk rise. Selected patients may also be candidates for roflumilast, long-term azithromycin, or other advanced therapy (GOLD, 2026).

Roflumilast

Roflumilast is an oral phosphodiesterase-4 inhibitor with anti-inflammatory effects. It has little role in day-to-day symptom relief and is used to reduce exacerbations in a selected phenotype. The assigned textbook emphasizes patients with chronic bronchitis, FEV1 below 50% predicted, prior COPD exacerbation requiring hospitalization, and ongoing long-acting bronchodilator therapy (Wietholter & Whetsel, 2026).

Adverse effects include diarrhea, nausea, abdominal discomfort, headache, weight loss, and insomnia. Psychiatric effects are also important; caution is warranted in underweight patients and patients with significant depression or related risk.

Ensifentrine

Ensifentrine is an inhaled dual phosphodiesterase-3/phosphodiesterase-4 (PDE3/PDE4) inhibitor. GOLD 2026 includes it as an option for patients with persistent dyspnea despite LABA/LAMA therapy after inhaler technique, adherence, device selection, nonpharmacologic treatment, and other causes of dyspnea have been addressed. Clinical trials demonstrated improvement in lung function, but GOLD notes that evidence is not yet sufficient to establish an exacerbation-reduction role in patients at high exacerbation risk (GOLD, 2026).

Alpha-1 Antitrypsin Deficiency and Augmentation Therapy

Alpha-1 antitrypsin (AAT) deficiency is a hereditary cause of COPD in which reduced antiprotease activity allows unopposed protease-mediated destruction of lung tissue. Identifying this phenotype matters because it creates a disease-specific therapeutic option that does not apply to routine smoking-related COPD (Wietholter & Whetsel, 2026).

AAT augmentation therapy consists of weekly intravenous infusions of pooled human AAT intended to maintain protective plasma concentrations. The assigned 2026 chapter describes benefit in slowing progression of lung disease and indicates that augmentation appears most beneficial in never-smokers or former smokers with moderate airflow obstruction, although it may be considered more broadly in AAT-deficient patients with progressive lung disease, particularly after smoking cessation. Common infusion-related adverse effects include chills, rash, fatigue, and gastrointestinal symptoms (Wietholter & Whetsel, 2026).

AAT augmentation is therefore a phenotype-specific therapy, not a general escalation step for COPD. Smoking cessation remains essential because ongoing smoke exposure accelerates protease-antiprotease injury and undermines disease-modifying treatment.

Methylxanthines and Other Nonroutine Therapies

Theophylline has a limited role because of its narrow therapeutic index, interaction burden, and risks of arrhythmias and seizures. It may occasionally be considered when patients cannot use or obtain preferred inhaled bronchodilators, but it is not a routine maintenance choice (Wietholter & Whetsel, 2026).

Leukotriene modifiers do not have an established routine role in COPD. Their usefulness in asthma should not be extrapolated to COPD because the inflammatory biology and evidence base differ. Other therapies should be selected only when a specific phenotype or indication is present rather than added empirically because symptoms persist.

Macrolide Prevention

Long-term azithromycin can reduce exacerbations in selected exacerbation-prone patients despite optimized therapy. Benefit appears greatest in patients who are not current smokers. Important tradeoffs include QTc prolongation, hearing loss, and antimicrobial resistance, so chronic macrolide therapy requires careful patient selection and monitoring (GOLD, 2026; Wietholter & Whetsel, 2026).

Biologic Therapy in Selected COPD

GOLD 2026 reserves biologic therapy for selected patients who continue to exacerbate despite optimized LABA/LAMA/ICS therapy and have evidence of eosinophilic inflammation. The pivotal dupilumab trials enrolled patients with chronic bronchitis, at least two moderate exacerbations or at least one severe exacerbation in the previous year, and blood eosinophils ≥300 cells/µL; treatment reduced exacerbations and improved lung function and health status. Mepolizumab trials likewise enrolled exacerbation-prone patients despite triple therapy, with benefit concentrated in patients with documented eosinophils ≥300 cells/µL. GOLD therefore suggests considering dupilumab for the chronic-bronchitis phenotype and mepolizumab for selected eosinophilic COPD when these high-risk features persist despite optimized inhaled treatment (GOLD, 2026).

COPD Exacerbations

GOLD defines a COPD exacerbation as worsening dyspnea and/or cough and sputum over several days, generally up to 14 days. Pneumonia, pulmonary embolism, acute heart failure, and pneumothorax can mimic or worsen exacerbation-like symptoms and should remain in the differential (GOLD, 2026).

Moderate or severe exacerbations are initially treated with a SABA, with or without a SAMA. Systemic corticosteroids are recommended for up to 5 days. Antibiotics are used when clinical features such as purulent sputum or prior respiratory infection history support bacterial involvement, with GOLD recommending a total antibiotic duration of approximately 5 days in appropriate patients. Methylxanthines are not recommended because of adverse effects. Acute respiratory failure may require high-flow oxygen or noninvasive ventilation (GOLD, 2026).

Long-acting bronchodilator therapy should be started or optimized promptly. At discharge after a moderate or severe exacerbation, patients with elevated eosinophils may warrant addition of ICS to dual bronchodilator therapy (GOLD, 2026).

Smoking Cessation

Smoking cessation is one of the most important disease-modifying interventions in COPD. Counseling plus pharmacotherapy improves quit rates. Appropriate options can include varenicline, sustained-release bupropion, nicotine replacement therapy, or combination nicotine replacement depending on patient-specific factors (GOLD, 2026; Wietholter & Whetsel, 2026).

Pulmonary Rehabilitation and Vaccination

Pulmonary rehabilitation improves exercise capacity, symptoms, and quality of life and is particularly important after an exacerbation. Vaccination should follow current local recommendations and includes influenza, pneumococcal, RSV, COVID-19, Tdap when indicated, and shingles vaccination as appropriate (GOLD, 2026).

Oxygen Therapy

Long-term oxygen therapy is reserved for severe chronic resting hypoxemia rather than routinely prescribed for moderate desaturation. GOLD identifies survival benefit in patients with PaO2 of 55 mmHg or lower, or below 60 mmHg when cor pulmonale or secondary polycythemia is present. Patients started on oxygen should be reassessed because oxygen requirements can change after recovery from an acute illness (GOLD, 2026).

Inhaler Selection and Monitoring

Device selection should account for inspiratory flow, dexterity, coordination, cognition, vision, cost, access, and patient preference. Nebulized long-acting bronchodilators may be useful when inhaler technique or inspiratory capacity is inadequate. Technique should be demonstrated and reassessed rather than assumed (GOLD, 2026; Wietholter & Whetsel, 2026).

Follow-up should assess symptom burden, activity limitation, exacerbations, adherence, inhaler technique, adverse effects, smoking status, oxygenation, comorbidities, and medication access. The assigned textbook recommends follow-up within about 1 month after an exacerbation, another assessment around 3 months, and stable-disease follow-up every 3–6 months, with periodic spirometry to assess progression (Wietholter & Whetsel, 2026).

High-Yield Distinctions

  • LABA/LAMA is the central maintenance bronchodilator combination for many symptomatic patients with COPD.
  • ICS is selective rather than routine and is guided by exacerbation history, eosinophils, asthma history, and pneumonia risk.
  • LABA/ICS is no longer the preferred COPD combination for new treatment decisions; triple therapy is favored when ICS is indicated.
  • Roflumilast targets a chronic-bronchitis, severe-obstruction, exacerbation-prone phenotype and is not a bronchodilator.
  • Ensifentrine is an inhaled PDE3/PDE4 option for persistent dyspnea despite LABA/LAMA, with a current role centered on symptom and lung-function improvement rather than established exacerbation prevention.
  • AAT augmentation is disease-specific therapy for selected patients with alpha-1 antitrypsin deficiency.
  • Theophylline and leukotriene modifiers do not have routine roles in contemporary COPD treatment.
  • Long-term azithromycin is reserved for selected exacerbation-prone patients because of QT, hearing, and resistance risks.
  • Biologic therapy is reserved for selected patients with at least two moderate or one severe exacerbation despite LABA/LAMA/ICS and documented eosinophilic inflammation; dupilumab is linked to chronic bronchitis, while mepolizumab is considered for selected eosinophilic COPD (GOLD, 2026).
  • Acute exacerbations generally use SABA with or without SAMA, short-course systemic corticosteroids, and antibiotics only when indicated.
  • Smoking cessation and pulmonary rehabilitation are core components of COPD management, not adjuncts after medications fail.
  • Inhaler technique and the cause of persistent dyspnea should be reassessed before repeated pharmacologic escalation.

Content last reviewed:

References

Global Initiative for Chronic Obstructive Lung Disease. (2026). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report. https://goldcopd.org/2026-gold-report-and-pocket-guide/

Wietholter, J. P., & Whetsel, T. R. (2026). Chronic obstructive pulmonary disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.harmacotherapy principles & practice (7th ed.). McGraw Hill.